Investigational drug combo for relapsed blood cancer
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial combines two investigational drugs to see if they are safe and effective for patients with two types of blood cancer: diffuse large B-cell lymphoma (DLBCL) or chronic lymphocytic leukemia (CLL) that has come back or stopped responding to standard treatments. It may offer a new option when other treatments have not worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have either relapsed or refractory (not responding to treatment) DLBCL or CLL that is confirmed to have a normal TP53 gene (no TP53 mutation).
- You have tried at least 2 prior treatments for DLBCL (or at least 1 prior treatment if you are not eligible for a stem cell transplant), or at least 1 prior treatment for CLL.
- You have an ECOG performance status of 0 to 2, which means you are generally able to take care of yourself and are up and about most of the day.
- Your blood counts, liver, and kidney function are within acceptable ranges, per the study doctor's assessment.
- You have not previously been treated with an MDM2 inhibitor or a BTK inhibitor (types of targeted drugs).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a combination of three targeted drugs (tafasitamab, acalabrutinib, and venetoclax) for people with CLL or SLL who have not yet received treatment. The goal is to see if this combination is effective and manageable.
This trial studies the combination of acalabrutinib and rituximab in older or frail people with newly diagnosed DLBCL (a type of lymphoma). It aims to see how well this treatment works and how safe it is for people who may not be able to tolerate standard chemotherapy.
This trial tests if adding another drug (X) to a standard chemotherapy mix (Pola-RCHP) works better for people with untreated diffuse large B-cell lymphoma (DLBCL). It is for those whose cancer DNA levels did not drop enough after the first round of treatment.
This trial tests different combinations of targeted drugs and chemotherapy for people newly diagnosed with a type of lymphoma called DLBCL. It aims to find which combination is more effective and safer.
This Phase 2 trial studies whether adding acalabrutinib to intensive chemo (DA-EPOCH-R or R-CHOP) works better for people newly diagnosed with aggressive diffuse large B-cell lymphoma (DLBCL) or related high-grade B-cell lymphomas. It may help shrink cancer and control the disease by targeting lymphoma in two different ways.
This trial tests a combination of chemotherapy drugs for people with a type of lymphoma called diffuse large B-cell lymphoma that has either come back early or never fully responded to first treatment. The goal is to see if this drug combination can help control the lymphoma.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.